Skip to main content
SpringerLink
Log in

Unsolved Problems and Future Prospects

  • Conference paper
Antiemetics in the Supportive Care of Cancer Patients

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 67 Accesses

Abstract

Although in the last few years the control of chemotherapy-induced nausea and vomiting has received increasing attention and new antiemetic drugs have been made available, the control of these symptoms is still far from being completely satisfactory.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Del Favero A, Roila F, Tonato M: Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilites. Drug Safety 1993 (9):410–428

    Article  PubMed  Google Scholar 

  2. Andrews PL, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR: Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992 (28A Suppll):2–6

    Article  Google Scholar 

  3. Freeman AJ, Cunningham KT, Tyers MB. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action. Anti-Cancer Drugs 1992 (3): 79–85

    Article  PubMed  CAS  Google Scholar 

  4. Marr HE, Davey PT, Bartlett AJ: Emerging differences between 5-HT3 receptor antagonists. Anti-Cancer Drugs 1991 (2):513–518

    Article  PubMed  CAS  Google Scholar 

  5. Marty M, d’Allens H, et le Groupe Multicentrique Francais: Etude randomisée en double-insu comparant l’efficacité de l’ondansetron selon deux modes d’administration: injection unique et perfusion continue. Cahiers Cancer 1990 (2):541–546

    Google Scholar 

  6. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belles, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, De Mulder PHM on behalf of the Ondansetron Study Group: Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992 (66): 192–197

    Article  PubMed  CAS  Google Scholar 

  7. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Bricker LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992 (10):1969–1975

    PubMed  CAS  Google Scholar 

  8. Ruff P, Paska W, Goedhals L, Pouillart P, Rivière A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, Butcher M, Forster J, McQuade B, on behalf of the Ondansetron and Granisetron Emesis Study Group: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994 (51):113–118

    Article  PubMed  CAS  Google Scholar 

  9. Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994(30A):1083–1088

    Article  PubMed  CAS  Google Scholar 

  10. Mantovani G, Macciò A, Curreli L, Bianchi A, Gebbia V, Testa A: Comparison of the effectiveness of three 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high-dose cisplatin) for treatment of primary head and neck cancer. Proc Am Soc Clin Oncol 1994 (13):428

    Google Scholar 

  11. Martoni A, Angelelli B, Guaraldi E, Strocchi E, Pannuti F: Granisetron vs ondansetron in the prevention of cisplatin-induced emesis. An open randomised cross-over study. Proc Am Soc Clin Oncol 1994(13):431

    Google Scholar 

  12. Jantunen IT, Kataja VV, Johansson RT: Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non-cisplatin-containing chemotherapy. Acta Oncologica 1992 (31):573–575

    Article  PubMed  CAS  Google Scholar 

  13. Bonneterre J, Hecquet B, on behalf of the French Northern Oncology Group: Granisetron iv compared with ondansetron iv plus tablets in the prevention of nausea and vomiting induced by a moderately emetogenic chemotherapy regimen: a randomized cross-over study. Presented at a Satellite to the 7th European Conference of Clinical Oncology and Cancer Nursing, Jerusalem, Israel (abstract book). Adelphi Communication, Macclesfield, UK 1993 pp 22–24

    Google Scholar 

  14. Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L: 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic che motherapy — a randomised study. Eur J Cancer 1993 (29A): 1669–1672

    Article  PubMed  CAS  Google Scholar 

  15. Campora E, Simoni C, Rosso R: Tropisetron versus ondansetron nella prevenzione e controllo dell’eme-si in pazienti sottoposte a chemioterapia con FAC/ FEC per carcinoma mammario metastatico o opera-to. Minerva Medica 1994 (85):25–31

    PubMed  CAS  Google Scholar 

  16. Massidda B, Laconi S, Foddi MR, Salamah K, Ionta MT: Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT3 receptors. Ann Oncol 1994 (5) Suppl.8:204

    Google Scholar 

  17. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, Latteri MA, Gebbia N: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994 (74): 1945–1952

    Article  PubMed  CAS  Google Scholar 

  18. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. New Engl J Med 1995 (332): 1–5

    Article  Google Scholar 

  19. Navari R, Hesketh T, Grote M, Cramer M, Law R, Whitmore J, Hahne W: A double-blind randomized, comparative iv study of single dose dolasetron vs ondansetron in preventing cisplatin-related emesis. Proc ASCO 1995 (14):522

    Google Scholar 

  20. Ritter H, Hall J, Mailliard J, Navari R, Friedman C, on behalf of the Granisetron Study Group: A comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. Proc ASCO 1995 (14):528

    Google Scholar 

  21. Roila F, De Angelis V, Cognetti F, Ricci S, Contu A, Nuzzo A, Picece V, Buzzi F, Clerico M, Tonato M: Ondansetron vs granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis. Proc ASCO 1995 (14):523

    Google Scholar 

  22. Baltzer L, Kris MG, Tyson LB, Rigas JR, Pisters KMW: The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer 1994 (73):720–723

    Article  PubMed  CAS  Google Scholar 

  23. Herrstedt J, Handberg J, Sigsgaard T, Hansen M, Dombemowsky P: Randomized, double-blind crossover trial of the antiemetic effect and tolerability of ondansetron (OND) vs OND plus the dopamine D2 antagonist metopimazine in patients receiving platinum-based chemotherapy. 6th International Symposium on Supportive Care in Cancer, March 2–5, New Orleans, 1994 P-63*

    Google Scholar 

  24. Barnes NM, Bunce KT, Naylor RJ, Rudd JA: The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 1991 (30): 1073–1083

    Article  PubMed  CAS  Google Scholar 

  25. Costello DJ and Borison HL: Naloxone antagonizes narcotic self-blockade of emesis in the cat. J Pharmacol Exp Ther 1977 (203):222–230

    PubMed  CAS  Google Scholar 

  26. Kobrinsky NL, Pruden PB, Cheang MS, Levitt M, Bishop AJ, Tenenbein M: Increased nausea and vomiting induced by naloxone in patients receiving cancer chemotherapy. Am J Ped Hem/Onc 1988 (10):206–208

    Article  CAS  Google Scholar 

  27. Lucot JB and Crampton GH: 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacology Biochemistry & Behavior 1989(33):627–631

    Article  CAS  Google Scholar 

  28. Lucot JB and Crampton GH: Buspirone blocks cis-platin-induced emesis in cats. J Clin Pharmacol 1987(27):817–818

    PubMed  CAS  Google Scholar 

  29. Borgeat A, Wilder-Smith OHG, Saiah M, Rifat K: Subhypnotic doses of propofol possess direct antiemetic properties. Anesth Analg 1992 (74):539–541

    Article  PubMed  CAS  Google Scholar 

  30. Borgeat A, Wilder-Smith OHG, Wilder-Smith CH, Forni M, Suter PM: Adjuvant propofol for refractory cisplatin-associated nausea and vomiting. Lancet 1992(340):679–680

    Article  PubMed  CAS  Google Scholar 

  31. Tattersall FD, Rycroft W, Hargreaves RJ: The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993 (259): r5–6

    Article  Google Scholar 

  32. Tattersall FD, Rycroft W, Hill RG: Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin, receptor antagonist CP-99,994. Neuropharmacology 1994 (33):259–260

    Article  PubMed  CAS  Google Scholar 

  33. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S: Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexa-methasone alone, and metoclopramide plus dexa-methasone in patients receiving cisplatin. J Clin Oncol 1989 (7): 108–114

    PubMed  CAS  Google Scholar 

  34. Moreno I, Roseli R, Abad A, Barnadas A, Carles J, Ribelles N, Solano V, Font A: Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992 (28A): 1344–1347

    Article  PubMed  CAS  Google Scholar 

  35. Italian Group for Antiemetic Research: Cisplatin-induced delayed emesis: Pattern and prognostic factors during three subsequent cycles. Ann Oncology 1994 (5):585–589

    Google Scholar 

  36. Navari R, Madajewicz S, Anderson N, Tchekmedyian N, Whaley W, Garewal H, Beck T, Anderson E, Liddle R, Ossi M: Oral ondansetron effectively controls cisplatin-induced delayed emesis. Proc ASCO 1995 (14):523

    Google Scholar 

  37. Kris MG, Pisters KMW, Hinkley L: Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994 (2):297–300

    Article  PubMed  CAS  Google Scholar 

  38. Rittenberg CN, Gralla RJ, Lettow LA, Cronin MD, Kardinal CG: New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109 patient trial. Proc ASCO 1995 (14):526

    Google Scholar 

  39. Roila F, Tonato M, Ballatori E, Del Favero A: Prevention of cisplatin-induced emesis. Lancet 1992(340):972

    Article  PubMed  CAS  Google Scholar 

  40. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L, Ballatori E, Tognoni G, Del Favero A: Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989 (7): 1693–1700

    PubMed  CAS  Google Scholar 

  41. Italian Group for Antiemetic Research: Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993 (11):2396–2404

    Google Scholar 

  42. Riviere A, on behalf of the Granisetron Study Group: Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994 (69):967–971

    Article  Google Scholar 

  43. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994(12):2204–2210

    PubMed  CAS  Google Scholar 

  44. Plosker GL and Milne RJ: Ondansetron: a pharma-coeconomic and quality of life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmaco Economics 1992 (2):285–301

    Article  CAS  Google Scholar 

  45. Ballatori E, Roila F, Berto P, De Angelis V, Neri COIivieri A, Tonato M, Del Favero A: Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens. A hospital perspective from Italy. PharmacoEconomics 1994 (5):227–237

    Article  PubMed  CAS  Google Scholar 

  46. Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, Sikora K, Carney DN, Cunningham D: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991(338):483–487

    Article  PubMed  CAS  Google Scholar 

  47. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P: Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993 (328): 1076–1080

    Article  PubMed  CAS  Google Scholar 

  48. Martin M, Diaz-Rubio E, Casado A, Dominguez S, Sastre J: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 1992 (28):430–432

    Article  PubMed  CAS  Google Scholar 

  49. Weissbach L, Multi-day Cisplatin Emesis Study Group: Ondansetron. Lancet 1991 (338):753

    Article  Google Scholar 

  50. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A: Ondansetron versus ondansetron, dexamethasone and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993 (11):2391–2395

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Internal Medicine and Oncological Sciences, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Albano Del Favero

  2. Medical Statistics Unit, Department of Internal Medicine and Public Health, University of L’Aquila, Italy

    Enzo Ballatori

  3. Medical Oncology Division, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Fausto Roila

Authors
  1. Albano Del Favero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enzo Ballatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fausto Roila
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Division, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Favero, A.D., Ballatori, E., Roila, F. (1996). Unsolved Problems and Future Prospects. In: Tonato, M. (eds) Antiemetics in the Supportive Care of Cancer Patients. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80240-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80240-9_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80242-3

  • Online ISBN: 978-3-642-80240-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation